Answers are grounded in this paper and cite their sources.
Mechanistic investigation reveals epidermal growth factor receptor signaling drives resistance to BRAF inhibitors in thyroid cancer, suggesting new combination strategies for targeted therapy.
The promise of personalized medicine is upon us, and in some cancers, targeted therapies are rapidly becoming the mainstay of treatment for selected patients based on their molecular profile. The protein kinase BRAF is a driver oncogene in both thyroid cancer and melanoma, but while drugs that target BRAF and its downstream signaling pathway are effective in melanoma, they are ineffective in thyroid cancer. In this issue of Cancer Discovery, Montero-Conde and colleagues investigate why thyroid cancer is resistant to BRAF inhibitors despite the presence of BRAF mutation.
No takes yet. Share an insight, caveat, or question.
Girotti et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: